vs

Side-by-side financial comparison of Pyxis Tankers Inc. (PXS) and Entrada Therapeutics, Inc. (TRDA). Click either name above to swap in a different company.

Entrada Therapeutics, Inc. is the larger business by last-quarter revenue ($20.6M vs $17.0M, roughly 1.2× Pyxis Tankers Inc.). Pyxis Tankers Inc. runs the higher net margin — 31.3% vs -84.4%, a 115.7% gap on every dollar of revenue.

Pyxis Tankers Inc. is an international maritime transport enterprise specializing in seaborne shipping of refined petroleum products and other bulk liquid cargoes. It operates a fleet of modern product tankers, serving global energy markets, with core business covering major trade routes across the Atlantic, Mediterranean and Asia-Pacific regions.

Entrada Therapeutics is a clinical-stage biotechnology firm developing transformative intracellular therapies for serious rare diseases and high-unmet-need disorders. Its pipeline covers neuromuscular, metabolic, and central nervous system segments, serving global patients via healthcare partnerships.

PXS vs TRDA — Head-to-Head

Bigger by revenue
TRDA
TRDA
1.2× larger
TRDA
$20.6M
$17.0M
PXS
Higher net margin
PXS
PXS
115.7% more per $
PXS
31.3%
-84.4%
TRDA

Income Statement — Q3 FY2022 vs Q1 FY2025

Metric
PXS
PXS
TRDA
TRDA
Revenue
$17.0M
$20.6M
Net Profit
$5.3M
$-17.3M
Gross Margin
Operating Margin
37.2%
-106.0%
Net Margin
31.3%
-84.4%
Revenue YoY
-65.2%
Net Profit YoY
-173.8%
EPS (diluted)
$0.44
$-0.42

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PXS
PXS
TRDA
TRDA
Q1 25
$20.6M
Q4 24
$37.4M
Q3 24
$19.6M
Q2 24
$94.7M
Q1 24
$59.1M
Q4 23
$41.8M
Q3 23
$43.7M
Q2 23
$18.2M
Net Profit
PXS
PXS
TRDA
TRDA
Q1 25
$-17.3M
Q4 24
$1.1M
Q3 24
$-14.0M
Q2 24
$55.0M
Q1 24
$23.5M
Q4 23
$-9.5M
Q3 23
$35.5M
Q2 23
$-25.9M
Operating Margin
PXS
PXS
TRDA
TRDA
Q1 25
-106.0%
Q4 24
-15.7%
Q3 24
-110.7%
Q2 24
56.4%
Q1 24
35.7%
Q4 23
11.7%
Q3 23
32.0%
Q2 23
-89.7%
Net Margin
PXS
PXS
TRDA
TRDA
Q1 25
-84.4%
Q4 24
3.0%
Q3 24
-71.7%
Q2 24
58.1%
Q1 24
39.7%
Q4 23
-22.8%
Q3 23
81.1%
Q2 23
-142.7%
EPS (diluted)
PXS
PXS
TRDA
TRDA
Q1 25
$-0.42
Q4 24
$-0.20
Q3 24
$-0.35
Q2 24
$1.55
Q1 24
$0.68
Q4 23
$-0.23
Q3 23
$1.02
Q2 23
$-0.78

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PXS
PXS
TRDA
TRDA
Cash + ST InvestmentsLiquidity on hand
$4.3M
$67.8M
Total DebtLower is stronger
$67.3M
Stockholders' EquityBook value
$54.9M
$417.3M
Total Assets
$138.1M
$486.5M
Debt / EquityLower = less leverage
1.23×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PXS
PXS
TRDA
TRDA
Q1 25
$67.8M
Q4 24
$101.2M
Q3 24
$78.0M
Q2 24
$185.3M
Q1 24
$68.4M
Q4 23
$67.6M
Q3 23
$51.9M
Q2 23
$79.7M
Stockholders' Equity
PXS
PXS
TRDA
TRDA
Q1 25
$417.3M
Q4 24
$428.7M
Q3 24
$422.4M
Q2 24
$429.9M
Q1 24
$269.4M
Q4 23
$242.4M
Q3 23
$246.7M
Q2 23
$206.9M
Total Assets
PXS
PXS
TRDA
TRDA
Q1 25
$486.5M
Q4 24
$526.3M
Q3 24
$554.6M
Q2 24
$582.0M
Q1 24
$510.8M
Q4 23
$469.2M
Q3 23
$485.0M
Q2 23
$494.0M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PXS
PXS
TRDA
TRDA
Operating Cash FlowLast quarter
$2.4M
$-38.5M
Free Cash FlowOCF − Capex
$-39.7M
FCF MarginFCF / Revenue
-192.9%
Capex IntensityCapex / Revenue
0.0%
5.6%
Cash ConversionOCF / Net Profit
0.45×
TTM Free Cash FlowTrailing 4 quarters
$-58.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PXS
PXS
TRDA
TRDA
Q1 25
$-38.5M
Q4 24
$-31.6M
Q3 24
$-24.3M
Q2 24
$39.8M
Q1 24
$-25.5M
Q4 23
$-4.0M
Q3 23
$-24.5M
Q2 23
$-35.1M
Free Cash Flow
PXS
PXS
TRDA
TRDA
Q1 25
$-39.7M
Q4 24
$-32.2M
Q3 24
$-24.9M
Q2 24
$38.8M
Q1 24
$-26.4M
Q4 23
$-5.0M
Q3 23
$-25.9M
Q2 23
$-36.6M
FCF Margin
PXS
PXS
TRDA
TRDA
Q1 25
-192.9%
Q4 24
-86.2%
Q3 24
-127.3%
Q2 24
41.0%
Q1 24
-44.6%
Q4 23
-11.9%
Q3 23
-59.3%
Q2 23
-201.5%
Capex Intensity
PXS
PXS
TRDA
TRDA
Q1 25
5.6%
Q4 24
1.7%
Q3 24
3.3%
Q2 24
1.1%
Q1 24
1.4%
Q4 23
2.3%
Q3 23
3.3%
Q2 23
8.4%
Cash Conversion
PXS
PXS
TRDA
TRDA
Q1 25
Q4 24
-27.94×
Q3 24
Q2 24
0.72×
Q1 24
-1.09×
Q4 23
Q3 23
-0.69×
Q2 23

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons